Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 17, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Repurchased: 1,100,000 ordinary shares of 25 pence each.
- Repurchase Date: September 17, 2008.
- Price per Share: 1,202.04 pence.
- Treasury Shares Held: 474,194,158 shares (representing 9.08% of total voting rights).
- Shares in Issue: 5,221,347,584 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's share capital through the cancellation of 1,100,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 474,194,158. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,221,347,584) for calculating disclosure thresholds under the Financial Services Authority's rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (9.08%).
- Note that this filing does not contain financial performance metrics; refer to Form 20-F for comprehensive financial data.